Mansour, A.; Mahmoud, M.Y.; Bakr, A.F.; Ghoniem, M.G.; Adam, F.A.; El-Sherbiny, I.M.
Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. Pharmaceutics 2023, 15, 994.
https://doi.org/10.3390/pharmaceutics15030994
AMA Style
Mansour A, Mahmoud MY, Bakr AF, Ghoniem MG, Adam FA, El-Sherbiny IM.
Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. Pharmaceutics. 2023; 15(3):994.
https://doi.org/10.3390/pharmaceutics15030994
Chicago/Turabian Style
Mansour, Amira, Mohamed Y. Mahmoud, Alaa F. Bakr, Monira G. Ghoniem, Fatima A. Adam, and Ibrahim M. El-Sherbiny.
2023. "Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668" Pharmaceutics 15, no. 3: 994.
https://doi.org/10.3390/pharmaceutics15030994
APA Style
Mansour, A., Mahmoud, M. Y., Bakr, A. F., Ghoniem, M. G., Adam, F. A., & El-Sherbiny, I. M.
(2023). Correction: Mansour et al. Dual-Enhanced Pluronic Nanoformulated Methotrexate-Based Treatment Approach for Breast Cancer: Development and Evaluation of In Vitro and In Vivo Efficiency. Pharmaceutics 2022, 14, 2668. Pharmaceutics, 15(3), 994.
https://doi.org/10.3390/pharmaceutics15030994
